Here’s what you’ll learn when you read this article: Why adding long-acting PYY to GLP-1 therapy showed only modest benefits and meaningful tolerability limits in human studies. How to interpret add-on obesity drug…
Here’s what you’ll learn when you read this article: Why targeting visceral and liver fat differs from appetite-first weight-loss drugs, and what early human data actually show. How INHBE and ALK7 gene-silencing works…
Here’s what you’ll learn when you read this article: How Wegovy tablets work, who qualifies under FDA criteria, and what the evidence shows about weight change and cardiovascular outcomes in eligible adults, using…
Here’s what you’ll learn when you read this article: ActRIIA/B inhibition shows promise in preserving lean muscle during rapid weight loss, unlike GLP-1 drugs alone. New therapies like LAE102 and dual ligand blockers…
Here’s what you’ll learn when you read this article: GLP‑1 and dual agonist drugs like tirzepatide have shown the ability to slow tumor growth in obesity‑linked cancers, especially in preclinical models. Early human…
Takeaways FGF21 and GDF15 analogs offer distinct mechanisms beyond GLP-1 for treating obesity and metabolic disease. Late-stage trials show promising effects on liver fat, appetite control, and thermogenesis with fewer GI side effects.…
Takeaways Brown fat activation raises calorie burn without suppressing appetite or affecting mood. Pharmacological BAT activation shows clinical promise with fewer side effects than older weight loss drugs. Combination strategies using BAT activators…
Takeaways MC4R agonists target the brain’s appetite center to support lasting weight maintenance after initial loss. Combining GLP‑1 and MC4R therapies enhances satiety control while minimizing metabolic rebound. Fountain of Youth SWFL leads…
Takeaways Bimagrumab plus GLP-1 therapy may preserve muscle while promoting near-total fat loss. Protecting lean mass improves long-term strength, metabolism, and quality of life. Functional outcomes, not just body composition, will shape future…
Takeaways RJVA-002 uses gene therapy to deliver GLP-1 and GIP directly from pancreatic beta cells in a nutrient-responsive way. Preclinical studies in obese mice show up to 30% body weight loss and improved…